1995
DOI: 10.1016/0003-4975(94)00725-m
|View full text |Cite
|
Sign up to set email alerts
|

Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

1995
1995
2010
2010

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 41 publications
(13 citation statements)
references
References 36 publications
0
13
0
Order By: Relevance
“…PMN sequestration could also be caused by other endogenous mediators such as platelet-activating factor (PAF). PAF is a potent PMN priming agent and CPB has been shown to increase PAF up to 350% [26]. Another possibility is that endotoxin or inflammatory mediators released secondary to endotoxin exposure cause cytoskeletal changes in neutrophils that result in increased stiffness and a decreased PMN deformability [27].…”
Section: Discussionmentioning
confidence: 99%
“…PMN sequestration could also be caused by other endogenous mediators such as platelet-activating factor (PAF). PAF is a potent PMN priming agent and CPB has been shown to increase PAF up to 350% [26]. Another possibility is that endotoxin or inflammatory mediators released secondary to endotoxin exposure cause cytoskeletal changes in neutrophils that result in increased stiffness and a decreased PMN deformability [27].…”
Section: Discussionmentioning
confidence: 99%
“…This is manifested by increased arterio‐venous oxygen difference, increased vascular resistance, leakage of fluid into the interstitial space, reduced pulmonary compliance (53, 78) and surfactant activity (79). Ischaemia/reperfusion injury, including washout of retained cells in the vascular bed during the bypass period and sequestered PMNs during the reperfusion period, is likely to be responsible for the tissue damage (80, 81). Only one study concerning paediatric cardiac surgery with CPB found any correlation between respiratory index and inflammatory markers (24), while other studies could not confirm this association (18, 20, 34, 82).…”
Section: Inflammatory Events At the Organ Levelmentioning
confidence: 99%
“…There are several studies pertaining to the prevention of CPB-induced lung injury: elimination of leukocytes in bypass circuit by anti-leukocyte agents (mustine hydrochloride) or a leukocyte filter (7), prevention of leukocyte adhesion to pulmonary endothelium (8), addition of oxygen free radical scavengers (vitamin E, coenzyme Q, vitamin C, glutathione) (9), utilization of cyclooxygenase antagonists (indomethacin), thromboxane A1 synthetase antagonist (dazmegral) (10), platelet activation factor inhibitors (11), and steroid administration (12, 13). Although these methods may help to protect the pulmonary vascular bed to some extent, the clinical application of these agents is limited due to unproven safety and cost-effectiveness.…”
Section: Introductionmentioning
confidence: 99%